Product Details
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
Description
The Human BTLA (Luc) Jurkat Reporter Cell was engineered to not only express the NFAT response element driving luciferase expressing systems, but also express the receptor full length human BTLA (Uniprot: Q7Z6A9 1). When cocultured with anti-human BTLA agonist antibody, the interaction of agonist antibody and BTLA on the surface of Human BTLA (Luc) Jurkat Reporter Cell results in a decrease in TCR signaling and NFAT mediated luminescence.
Application
• Screen for anti-human BTLA agonist antibody.
• Screen for antibody blocking the BTLA/HVEM binding.

Growth Properties
Suspension
Selection Marker
Puromycin (5 μg/mL) + Hygromycin B (20 μg/mL)
Complete Growth Medium
RPMI-1640 + 10% FBS
Freeze Medium
Serum-free cell cryopreservation medium
Quantity
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
Storage
Frozen in liquid nitrogen.
Mycoplasma Testing
Negative
Sterility Testing
Negative
Instructions for Use
See data sheet for detailed culturing and assay protocol.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Receptor Assay

Expression analysis of human BTLA on Human BTLA (Luc) Jurkat Reporter Cell by FACS.
Human BTLA (Luc) Jurkat Reporter Cell or negative control cell were stained with PE-labeled anti-human BTLA antibody.Protocol
Application

Inhibition of TCR activator-induced reporter activity by anti-human BTLA antibody.
This reporter cell was incubated with serial dilutions of antibodies stimulated by TCR activator. The EC50 of anti-human BTLA antibody is approximately 0.0037 μg/mL.Protocol
Passage Stability

Passage stability analysis by anti-human BTLA antibody stimulation.
The continuously growing Human BTLA (Luc) Jurkat Reporter Cell was stimulated with serial dilutions of antibodies. Anti-human BTLA antibody stimulated response demonstrates passage stabilization (EC50 and neutralization) across passage 5-23.Protocol
Customer Reviews Writing Reviews

Important Statement
Limited Use&License Disclosure
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
- If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
- Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
- This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
Recent Advances
- English Name:
B- and T-lymphocyte attenuator
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
6 Details
- Highest Development Stage:
Phase 3 Clinical




















